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a hospital performing 50 knee and 50 hip surgeries every year, this potential for cost-
offsets would be of (-R$108,850). This would vary a lot for the perspective of HMOs 
and hospitals of different sizes, as well as depending on the costs of each decision 
maker, demanding constant customization of parameters. CONCLUSIONS: The use 
of IEI makes the pharmacoeconomic studies results more intelligible to decision 
makers, permitting them to foresee their actual application on a real practice, in dif-
ferent scenarios.
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BACKGROUND: Use of electronic health care databases to examine pharmaceutical 
use and effects faces limitations inherent in the source of data. Medical records docu-
ment prescribing but not consumption of medication; administrative databases docu-
ment dispensing but not the original intent of the prescriber. OBJECTIVES: To 
evaluate a patient-level linked database of electronic medical records (EMR) and 
administrative claim for use in measuring both prescribing and dispensing of pharma-
ceuticals. METHODS: Claims data from Thomson Reuters MarketScan database were 
linked to the GE Centricity EMR database using probabilistic methods to overcome 
the de-identiﬁ cation required of both databases under US privacy laws. Patient-level 
records were matched based on demographic characteristics and calendar dates of 
physician visits. Multiple visits were required to reduce the likelihood of mismatches. 
The agreement between prescribing records in the EMR and claims for dispensing of 
medication was explored in the context of self-administered medication for osteopo-
rosis, including bisphosphonates and raloxifene. RESULTS: Using data from 2004–
2009, 219,529 patients were matched between the two data sources. Mean age was 
43 years and 57% were female. We identiﬁ ed 2,331 patients whose medical record 
showed new prescriptions for bisphosphonates or raloxifene (no evidence of use in 
the prior 180 days). Pharmacy claims indicated these prescriptions were ﬁ lled by 56% 
of patients within 7 days, 75% within 30 days, and 86% within 90 days. CONCLU-
SIONS: It is to be expected that there will be some degree of noncompliance, hence 
incomplete ﬁ lling of prescriptions, as observed. The lag from dispensing to prescribing 
among many patients is also consistent with use of samples for initial prescriptions. 
Overall, the example of osteoporosis therapy shows consistency between prescribing 
in EMR data and dispensing in claims data among a sample of probabilistically linked 
patient records.
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OBJECTIVES: Controlling for disease severity in observational studies is crucial to 
get an estimate with no selection bias. However, outcomes research studies using 
claims data, contain no information about disease severity. Therefore, comorbid scores 
are used for a proxy for the disease severity. There exists no severity score speciﬁ c for 
rheumatoid arthritis (RA). The goal of this study was to develop a severity index for 
rheumatoid arthritis (SIFRA) for private health care claims data. METHODS: We 
extracted the following variables related to rheumatoid arthritis from the claims data: 
total number of synthetic disease-modifying anti-rheumatic drugs (DMARDs), total 
number of biological DMARDs, tests for C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR) ordered, rehabilitation visits, rheumatology visits, Felty’s 
syndrome and Sjogren’s syndrome, pulmonary, soft tissue nodules, joint surgery, 
number of platelet counts and chemical panels ordered, and rheumatoid factors 
testing. a linear regression model was used to create the severity score. The severity 
score was compared with the rheumatoid arthritis medical records-based index of 
severity (RARBIS) and currently-used comorbidity scores to proxy severity in out-
comes research studies related with rheumatoid arthritis. RESULTS: According to the 
Akaike Information Criterion (AIC), Bayesian Information Criterion (BIC), log likeli-
hood function, R-squared values and average squared prediction error, SIFRA per-
formed better than RARBIS, Charlson Comorbidity Score (CCI), Elixhauser 
comorbidity score and Chronic disease score. Spearman correlation with RARBIS was 
0.65 and signiﬁ cant. However, the correlation with the Charlson Comorbidity Index 
(0.1, p = 0.6521), Elixhauser Index (0.15, p = 0.5312) and Chronic disease score (0.13, 
p = 0.6011) were low and insigniﬁ cant. CONCLUSIONS: Comorbidity scores (Charl-
son, Elixhauser or Chronic Disease Scores) commonly used in outcomes research are 
inadequate to be proxy variable for RA patients. SIFRA, at least for rheumatoid 
arthritis, controls for disease severity better than any other commonly used measure.
PMS75
MODELING OF RHEUMATOID ARTHRITIS: A METHODOLOGICAL 
APPROACH
Taylor MJ1, Righetti C1, Conway P2, Lebmeier M3
1University of York, York, UK; 2Wyeth Pharmaceuticals, Maidenhead, UK; 3Bristol-Myers 
Squibb Pharmaceuticals Ltd, Uxbridge, Middlesex, UK
OBJECTIVES: Reimbursement agencies like the United Kingdom (UK) National Insti-
tute for health and Clinical Excellence (NICE) use mathematical modelling to analyze 
the costs and beneﬁ ts of health care technologies. The structure of these models is not 
pre-speciﬁ ed, but dependent on the requirements of the decision problem on hand. 
Various decision-analytic models have been developed to assess the potential clinical 
and economic beneﬁ ts of several RA treatment regimes, including anti-TNF agents 
and early use of disease-modifying anti-rheumatic drugs (DMARDs). The main objec-
tive is to provide a guide on how to model treatment options for early rheumatoid 
arthritis, in particular etanercept. Thus, it sought to address the methodological issues 
relating to the choice of modeling technique. RESULTS: Previous analyses have used 
a variety of modelling approaches to model treatment options for RA. The rationale 
for the choice of model structure is rarely discussed in published studies and can affect 
the results produced. Advances in the treatment of RA make it necessary to develop 
a model which is ﬂ exible enough to account for different attributes (e.g. clinical remis-
sion, radiographic non-progression, and functional status), but does not increase the 
complexity of the model to an amount where it becomes too difﬁ cult to populate it 
with relevant data. Individual level models offer a solution to this problem by simulat-
ing the progression of each individual with different characteristics, where non-
Markovian distributions allow greater ﬂ exibility in modelling the timing of events. 
Further, based on the characteristics of the disease, the model should assume indepen-
dence between individuals, whilst, based on its treatment options, as assessment of 
adequate treatment response is important, time should be modeled. CONCLUSIONS: 
This work suggests that future analyses should use individual sampling models (e.g. 
simulated patient-level Markov models) for modelling the costs and beneﬁ ts of treat-
ments for RA.
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OBJECTIVES: Mapping from disease-speciﬁ c to utility measures is a research area 
gaining increasing attention. However, few studies have assessed the longitudinal 
validity of mapping models and none, to our knowledge, have compared models 
derived from baseline and post-intervention patient data. This study examined models 
derived from time-differing patient data, for mapping the Modiﬁ ed Health Assessment 
Questionnaire (MHAQ) on to the EQ-5D. METHODS: A total of 120 rheumatoid 
arthritis patients (60.0% female, mean age 59.0) completed the MHAQ and EQ-5D 
at baseline, and 3, 6 and 12 months after administration of an anti-TNFa or another 
biological agent. OLS regression produced mapping equations from baseline and post-
intervention data. Model predictive ability and explanatory power were assessed by 
root mean square error (RMSE) and adjusted R2 respectively. Pearson’s r and intra-
class correlation coefﬁ cient (ICC) assessed association and level of agreement between 
predicted and reported utilities. RESULTS: R2 (baseline, 3, 6 and to 12 months) was 
0.452, 0.418, 0.541 and 0.413 respectively, whereas prediction errors were 13.0%, 
11.1%, 8.1% and 7.2%. All equations produced a range of scores comparable to 
those achieved by the standard EQ-5D scoring algorithm, as well as strong correlations 
and agreement between reported and predicted utilities. The baseline and 12-month 
models appeared to under- and overestimate EQ-5D scores respectively, whereas the 
6-month model generated the smallest differences, typically less than the minimally 
important difference for the EQ-5D (0.03). CONCLUSIONS: Baseline data, which 
typically corresponds to lower patient HRQOL, may give mapping equations with 
compromised predictive ability, compared to models generated from post-intervention 
data, and this study showed that this factor is worth examining when longitudinal 
data are available. The next step in this line of research is to test QALY estimates and 
cost-utility increments derived from baseline and post-intervention mapping 
algorithms.
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BACKGROUND: An important consequence of rheumatoid arthritis (RA) is disabil-
ity, traditionally assessed by the Health Assessment Questionnaire (HAQ), which 
captures the physical component. Disability can also be evaluated by restricted per-
formance of social roles and those predictors haven’t been extensively studied. OBJEC-
TIVES: Determinants of social roles, among RA patients, as evaluated by paid work 
and social functioning were studied. METHODS: A total of 1,140 RA patients from 
the NDB-Portugal longitudinal cohort were analyzed. Univariate (UV) and Multivari-
ate (MV) generalized estimating equations were used to assess whether the following 
factors were determinants of paid work (1 = yes 0 = no, OR; 95%CI) and of SF-36 
social functioning (0–100, 100 is best, β; 95%CI): age, sex, marital status, educational 
level, number of people living in patient’s household, dependence on others, RA dura-
tion, number of major comorbidities, TNF, anxiolytic and/or antidepressant use, 
HAQ, disease activity (RADAI), quality of life (VASQOL), pain, fatigue and sleep 
disturbances (VAS scales, 0–10, 10 is worst). RESULTS: In MV analysis the odds of 
having a form of paid work increased with higher education (1.17; 1.12, 1.22) and 
better VASQOL (1.92; 1.15, 3.20) and decreased with higher age (0.91; 0.90, 0.93), 
